CureVac: CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at
Based in...
Clinical Stage
Phase III
Disease Space
Anti-infectives, Antivirals, Autoimmune, COVID-19, Infectious Disease, Oncology, Ophthalmology
Investment Strategy
Under the Radar
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Vaccine
Friedrich-Miescher-Str. 15
Tübingen, 72076

Company Participants at Solebury 1x1 Management Access Event 2023

  • Antony Blanc, CBO/COO
  • Franz-Werner Haas, Chief Executive Officer, Chief Operating Officer
  • Pierre Kemula, CFO
  • Ronald Plasterk, Sr VP Innovation and Science and CEO CureVac Netherlands
  • Sarah Fakih, Vice President Investor Relations

Top 10 Holders of CureVac N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
RA Capital Management LP 5.52 12,245,955 0.00 13F 3/31/23
T. Rowe Price Associates, Inc. (Investment Management) 1.72 3,813,896 0.00 13F 3/31/23
Avidity Partners Management LP 1.60 3,550,000 0.00 13F 3/31/23
Citadel Advisors LLC (13f Subfiler) 1.32 2,935,303 0.00 13F 3/31/23
Millennium Management LLC 0.81 1,790,308 0.00 13F 3/31/23
Bill & Melinda Gates Foundation 0.73 1,625,943 0.00 13F 3/31/23
Camber Capital Management LP 0.56 1,250,000 0.00 13F 3/31/23
Balyasny Asset Management LP 0.50 1,115,763 0.00 13F 3/31/23
Alyeska Investment Group LP 0.48 1,060,382 0.00 13F 3/31/23
BlackRock Fund Advisors 0.41 919,210 0.00 13F 3/31/23
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.